Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brexpiprazole in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients, or inpatients at the time of informed consent whose treatment status can be successfully shifted to outpatient status before enrollment in the antidepressant treatment period~* Male and female patients ≥ 20 to \< 65 years of age (at the time of informed consent)~* Patients who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial~* Patients with a DSM-5 classification-based diagnosis of major depressive disorder, single episode or major depressive disorder, recurrent episode, and whose current episode has persisted for at least 8 weeks~Exclusion Criteria:~* Women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at screening~* Sexually active male subjects or sexually active female subjects of childbearing potential, who will not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after the final~IMP administration. For birth control, 2 of the following methods must be used:~vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.~* Patients with a treatment history showing that all antidepressants (including those not used for the current major depressive episode) cannot be tolerated~* Patients with a history of electroconvulsive therapy~* Patients with a diagnosis of any of the following diseases according to DSM-5~  1. Neurocognitive disorders~ 2. Schizophrenia spectrum and other psychotic disorders~ 3. Bipolar and related disorders~ 4. Feeding and eating disorders~ 5. Obsessive-compulsive disorder~ 6. Panic disorder~ 7. Posttraumatic stress disorder

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole 1mg (Type: EXPERIMENTAL): Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
- Brexpiprazole 2mg (Type: EXPERIMENTAL): Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
- Placebo (Type: PLACEBO_COMPARATOR): Tablets, Oral, once daily, 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).